PlainPharmaWatch

CMS Open Payments · Tool

Y-mAbs Therapeutics, Inc. vs Radiometer America, Inc

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Y-mAbs Therapeutics, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 2,623, versus 850 for the other company. Its single largest recorded recipient represents 47.1% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Y-mAbs Therapeutics, Inc.
HHI 2,623 · top recipient 47.1%
Ranked #629 of 1,838 companies by HHI
Radiometer America, Inc
HHI 850 · top recipient 14.3%
Ranked #1,090 of 1,838 companies by HHI

Payment Overview

Total Payments
$1.7M
% of Industry
0.0%
Transactions
638
Avg per Transaction
$2.7K
Recipients
159
Avg per Recipient
$10.9K
Payment Types
3
Top Payment Type
Consulting Fee
Total Payments
$1.7M
% of Industry
0.0%
Transactions
199
Avg per Transaction
$8.7K
Recipients
84
Avg per Recipient
$20.7K
Payment Types
6
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Y-mAbs Therapeutics, Inc. vs Radiometer America, Inc - total reported payments in CMS Open Payments PY2024

Radiometer America, Inc$1.7MY-mAbs Therapeutics, Inc.$1.7M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Y-mAbs Therapeutics, Inc.

Consulting Fee $196.8K

94.3%

Food and Beverage $9.5K

4.5%

Grant $2.5K

1.2%

Radiometer America, Inc

Consulting Fee $44.9K

69.7%

Compensation for Faculty or Speaker (Medical Education) $10.7K

16.6%

Food and Beverage $3.9K

6.0%

Compensation for Services Other Than Consulting $2.9K

4.6%

Travel and Lodging $1.5K

2.3%

Education $454.15

0.7%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Y-mAbs Therapeutics, Inc.

  1. 1

    EVGENIYA ANGELOVA

    $98,400.00 · 4 txns

  2. 2

    STEVEN LARSON

    $27,775.00 · 4 txns

  3. 3

    HATICE GUR

    $26,000.00 · 1 txns

  4. 4

    ROLAND CHU

    $9,533.24 · 3 txns

  5. 5

    LEONORA ROSE SLATNICK

    $9,018.22 · 4 txns

Radiometer America, Inc

  1. 1

    JAN BAKKER

    $9,174.15 · 2 txns

  2. 2

    WILLIAM PEACOCK

    $9,000.00 · 3 txns

  3. 3

    CARLO BARTOLI

    $8,446.23 · 3 txns

  4. 4

    DAVID KONG

    $6,391.78 · 3 txns

  5. 5

    HEIDI DALTON

    $5,217.18 · 2 txns

Summary Comparison

Metric Y-mAbs Therapeutics, Inc. Radiometer America, Inc
Total Payments $1.7M $1.7M
% of Industry Total 0.0% 0.0%
Transaction Count 638 199
Avg per Transaction $2.7K $8.7K
Recipient Count 159 84
Avg per Recipient $10.9K $20.7K
Payment Type Count 3 6
Top Payment Type Consulting Fee Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.